%PDF-1.4
%
62 0 obj
<>
endobj
59 0 obj
<>
endobj
122 0 obj
<>stream
Acrobat Distiller 4.05 for Macintosh
2005-07-05T16:10:51Z
2024-03-29T08:45:40-07:00
QuarkXPressª: AdobePS 8.8.0 (301)
2024-03-29T08:45:40-07:00
application/pdf
Heather
2004-744.aug
uuid:54520973-1dd2-11b2-0a00-4b08275dc400
uuid:54520976-1dd2-11b2-0a00-810000000000
endstream
endobj
48 0 obj
<>
endobj
49 0 obj
<>
endobj
63 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 32 0 R/Type/Page>>
endobj
1 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 34 0 R/Type/Page>>
endobj
4 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 36 0 R/Type/Page>>
endobj
7 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Thumb 38 0 R/Type/Page>>
endobj
26 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 40 0 R/Type/Page>>
endobj
29 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 42 0 R/Type/Page>>
endobj
144 0 obj
[148 0 R]
endobj
145 0 obj
<>stream
1 g
/GS0 gs
0 792 m
0 792 l
f
q
13.5 787.5 585 -783 re
W n
q
0 792.03 612 -792 re
W n
BT
0 0 0 1 k
/GS1 gs
/T1_0 1 Tf
-0.00011 Tc 0.02499 Tw 8 0 0 8 57 736.1941 Tm
[(10.)-875.1 (Beaton DE, Bombardier C, Guillemin F)79.7 (, Ferraz MB. Guidelines for)]TJ
2.175 -1.25 Td
(the process of cross-cultural adaptation of self-report measures.)Tj
0 Tc 0 -1.25 TD
(Spine 2000;25:3186-91.)Tj
-0.00011 Tc -2.1381 -1.25 Td
[(1)36.8 (1)-0.1 (.)-875.1 (Hakkinen )54.8 (A, Kautiainen H, Hannonen P)110.7 (, et al. Pain and joint )]TJ
2.1381 -1.25 Td
(mobility explain individual subdimensions of the Health)Tj
T*
(Assessment Questionnaire \(HAQ\) disability index in patients with)Tj
0 Tc T*
[(rheumatoid arthritis. )54.8 (Ann Rheum Dis 2005;64:59-63. Epub 2004)]TJ
T*
(May 6.)Tj
-0.00011 Tc -2.175 -1.25 Td
[(12.)-875.1 (Arkela-Kautiainen M, Kauppi M, Heikkil\212 S, et al. Evaluation of)]TJ
2.175 -1.25 Td
[(the )54.8 (Arthritis Impact Measurement Scales \(AIMS2\) in Finnish)]TJ
T*
(patients with rheumatoid arthritis. Scand J Rheumatol )Tj
0 Tc 0 Tw T*
(2003;32:300-5.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(13.)-875.1 (Steinbocker O, )17.7 (T)35 (raeger CH, Batterman RC. )17.7 (Therapeutic criteria in)]TJ
2.175 -1.25 Td
[(rheumatoid arthritis. JAMA)-220.2 (1949;140:659-62.)]TJ
-2.175 -1.25 Td
[(14.)-875.1 (Pioro MH, Kwoh CK. Update on measurement of relevant )]TJ
2.175 -1.25 Td
[(outcomes in rheumatology)64.8 (. Curr Opin Rheumatol 1996;8:101-5.)]TJ
-2.175 -1.25 Td
[(15.)-875.1 (Kwoh CK, Ibrahim SA. Rheumatology patient and physician )]TJ
2.175 -1.25 Td
(concordance with respect to important health and symptom status)Tj
T*
[(outcomes. )54.8 (Arthritis Rheum 2001;45:372-7.)]TJ
30.825 22.5 Td
[(16.)-875.1 (Katz JN, Larson MG, Phillips CB, Fossel )54.8 (AH, Liang MH.)]TJ
2.175 -1.25 Td
(Comparative measurement sensitivity of short and longer health)Tj
T*
(status instruments. Med Care 1992;30:917-25.)Tj
-2.175 -1.25 Td
[(17.)-875.1 (Stucki G, Stucki S, Br\237hlmann P)110.7 (, Michel BA. Ceiling ef)17.7 (fects of the)]TJ
2.175 -1.25 Td
[(Health )54.8 (Assessment Questionnaire and its modified version in some)]TJ
T*
[(ambulatory rheumatoid arthritis patients. )54.8 (Ann Rheum Dis)]TJ
0 Tc 0 Tw T*
(1995;54:461-5.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(18.)-875.1 (Serrano MAB, Fabregat JB, Garz\227n JO. Should the MHAQ ever be)]TJ
0 Tc 2.175 -1.25 Td
[(used? )54.9 (Ann Rheum Dis 1996;55:271-2.)]TJ
-0.00011 Tc -2.175 -1.25 Td
[(19.)-875.1 (W)79.9 (olfe F)79.7 (.)-0.1 ( )54.8 (A)-220.1 (brief health status instrument: CLINHAQ [abstract].)]TJ
2.175 -1.25 Td
(Arthritis Rheum 1989;32 Suppl:S99.)Tj
-2.175 -1.25 Td
[(20.)-875.1 (Houssien DA, McKenna SP)110.7 (, Scott DL. )17.7 (The Nottingham Health)]TJ
2.175 -1.25 Td
(Profile as a measure of disease activity and outcome in rheumatoid)Tj
T*
(arthritis. Br J Rheumatol 1997;36:69-73.)Tj
-2.175 -1.25 Td
[(21.)-875.1 (Pincus )17.7 (T)74 (, Callahan LF)79.7 (, Brooks RH, Fuchs HA, Olsen NJ, Kaye JJ.)]TJ
2.175 -1.25 Td
(Self-report questionnaire scores in rheumatoid arthritis compared)Tj
T*
(with traditional physical, radiographic, and laboratory measures.)Tj
T*
[(Ann Intern Med 1989;1)36.8 (10:259-66.)]TJ
ET
0 0 0 1 K
53.468 76.5 m
558.468 76.5 l
S
0 0 0 0 k
494.29 69.365 64.178 -15.665 re
f*
BT
0 0 0 1 k
/T1_1 1 Tf
0 Tc 0 Tw 8 0 0 8 541.468 56.4344 Tm
(1431)Tj
ET
0 0 0 0 k
53.532 70.509 216 -16.434 re
f*
BT
0 0 0 1 k
/T1_1 1 Tf
-0.00011 Tc 0.02499 Tw 8 0 0 8 54.532 56.8093 Tm
(Arkela-Kautiainen, et al: MDHAQ in Finnish patients with RA)Tj
ET
0 0 0 0 k
/GS0 gs
103.782 82.35 407.5 -10.833 re
f*
0.5 w
/GS1 gs
103.782 82.35 407.5 -10.833 re
S
Q
Q
q
0 0 612 792 re
W n
BT
0 g
/GS2 gs
/T1_2 8 Tf
108.828 74 Td
(Personal non-commercial use only. The Journal of Rheumatology Copyright\
\251 2005. All rights reserved.)Tj
ET
Q
BT
0 g
/GS2 gs
/T1_3 1 Tf
10 0 0 10 540 17 Tm
( )Tj
0 0.48627 0.77255 rg
/GS2 gs
-7.22298 0 Td
(www.jrheum.org)Tj
0 g
/GS2 gs
-16.72996 0 Td
(Downloaded on March 29, 2024 from )Tj
ET
endstream
endobj
42 0 obj
<>stream
8;Z\5>7uNA&DR(hE3H%$-;@,FAV:Rg7VZcrqoZ3V)F&n2=Is(QTB2l=Y!;2PcIUfD
Roh0km3^).:nR:nn6Sg![`%o8lm*T+^B[`8"H?*c:WA=p,.>(PfNZfio[2->,n7*Q
Z4n>`V1[&r]ka.+0sV?rW:Sd/]a=#dFbh/:L&F)2RmNk'XBp1>D!qIhCJRK.87t`#
ZG!'rb%p23QF[>l0-fbL6`sY<[*TL;3d%9@R;Be].R>\!brj!(ind3,-'qBQN1Ri$
,naLa"(#k'j<+]]MKEGa`20#WEB]D6Fs@[oiju>kFmJEf>@2O`-(kuH9
L1(pRnKHlpG-.9XIoTa1o1FgMpKZS`ogD!`TAVF(T!WmZ~>
endstream
endobj
46 0 obj
[/Indexed/DeviceRGB 255 45 0 R]
endobj
45 0 obj
<>stream
J,g]g+e/h_!_gCtO=0f)$P%cIi8Zdfc5&3j_8$7g.@L`YKUJNGBP\poR=_;Dl'P(T
(7Boo^^S:71(MN]ZQX/+Cbu.lK"p74pe1T%s.DY%&\1TdJhr54.M9au6>79n6`Q:4
PbLSZTLEE(8E@'*1mg_*eTnN*;*'V3+gm-EEetX%;Bo$ur2ss*N`.-!.kG_q6GDD'
dKoL!8Ka#EV,@V!\j8ZFbp6EE<9cn=N6j0nf;(&;QU6bUD')c@\
9-d\DA=cZ0Q>gIM$$;cd2O@&a;X,Nn_aP(]I1aRc(K1^ue>
gF/(+GaKo$qneLWDrQ#;5\S(\$q'4Q,85`-8;S(=Z"WSBOV*FM)4,?B],R
endstream
endobj
70 0 obj
<>
endobj
71 0 obj
<>
endobj
109 0 obj
<>
endobj
127 0 obj
<>
endobj
72 0 obj
<>
endobj
103 0 obj
<>stream
HtTyPadV bE7+;#\"Ȉ""k!Z\EF%jvMKjӰ#JU{}'lm0H4mV̋T%)S؉=EtnȎhGutEP҇b2Z%.2*:-(HIשvIpϟMրƩcܦt}2IϭNU4j"E\Rԥ
7TzNq$.SsTtq:N%b8BR9`.qVc" z0[[)P1ł1%YEE_lV\y+։m*q?L0~$A2j#YI(
":!j<>F1֫'X
pv0RSsy[dk+4TۋvHWa+KKsŒ2%,c6k]
R}ܠR3rQJ@$D0]饇6}?C
f&;Rs}C>,G)x:Ҽ6m>|!?S|G֥_0FbpWb6